Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia / Donald E. Addington en Journal of Clinical Psychopharmacology, Año 2002 - Vol. 22 - No. 2 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 2 (Febrero) . - pp. 20-25 Título : Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia Tipo de documento: texto impreso Autores: Donald E. Addington, Autor ; Jean Addington, Autor ; Scott B. Patten, Autor Fecha de publicación: 2023 Artículo en la página: pp. 20-25 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno Depresivo Mayor, Esquizofrenia, Psicología esquizofrénica, Sertralina. Resumen: The effectiveness of selective serotonin reuptake inhibitors for depression in remitted schizophrenia has not been clearly demonstrated. A randomized, double-blind, prospective placebo-controlled study was performed of 48 subjects meeting DSM-IV criteria for both schizophrenia in remission and for a major depressive episode. Link: ./index.php?lvl=notice_display&id=31089 [artículo] Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia [texto impreso] / Donald E. Addington, Autor ; Jean Addington, Autor ; Scott B. Patten, Autor . - 2023 . - pp. 20-25. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 2 (Febrero) . - pp. 20-25 Palabras clave: Trastorno Depresivo Mayor, Esquizofrenia, Psicología esquizofrénica, Sertralina. Resumen: The effectiveness of selective serotonin reuptake inhibitors for depression in remitted schizophrenia has not been clearly demonstrated. A randomized, double-blind, prospective placebo-controlled study was performed of 48 subjects meeting DSM-IV criteria for both schizophrenia in remission and for a major depressive episode. Link: ./index.php?lvl=notice_display&id=31089

Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia / Donald E. Addington en The Journal of Clinical Psychiatry, Año 2011 - Vol.72 - No.1 (Enero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No.1 (Enero) . - pp. 75-80 Título : Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia Tipo de documento: texto impreso Autores: Donald E. Addington, Autor ; Somaia Mohamed, Autor ; Robert A. Rosenheck, Autor Fecha de publicación: 2022 Artículo en la página: pp. 75-80 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Enfermedad crónica, Depresión, Trastorno depresivo mayor, Farmacoterapia, Perfenazina, Esquizofrenia. Resumen: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. Link: ./index.php?lvl=notice_display&id=27929 [artículo] Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia [texto impreso] / Donald E. Addington, Autor ; Somaia Mohamed, Autor ; Robert A. Rosenheck, Autor . - 2022 . - pp. 75-80. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No.1 (Enero) . - pp. 75-80 Palabras clave: Antipsicóticos, Enfermedad crónica, Depresión, Trastorno depresivo mayor, Farmacoterapia, Perfenazina, Esquizofrenia. Resumen: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. Link: ./index.php?lvl=notice_display&id=27929

---

1 (1 - 2 / 2)